Understand the source comparison
Mechanism Comparison: How Each Peptide Acts on the Gut Barrier
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from gastric juice protein BPC. It promotes angiogenesis through VEGF (vascular endothelial growth factor) upregulation and accelerates collagen deposition via fibroblast acti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from gastric juice protein BPC. It promotes angiogenesis through VEGF (vascular endothelial growth factor) upregulation and accelerates collagen deposition via fibroblast activation. Both critical for repairing mucosal lesions and restoring barrier continuity after chronic inflammation or NSAID-induced damage. Research published in Journal of Physiology and Pharmacology (2020) demonstrated that BPC-157 restored intestinal anastomosis healing in rat models by increasing tensile strength at the wound site by 42% compared to saline controls. The peptide doesn't suppress bacteria directly; it rebuilds the physical architecture bacteria exploit when the barrier is compromised.
- KPV (lysine-proline-valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). It functions as an immune modulator by inhibiting NF-κB translocation into the nucleus. The transcription factor responsible for pro-inflammatory cytokine expression. In a 2019 study from Inflammatory Bowel Diseases, oral KPV reduced colonic TNF-α levels by 58% and IL-6 by 47% in DSS-induced colitis models. KPV's anti-inflammatory action is especially relevant in SIBO because bacterial endotoxins (lipopolysaccharides) trigger the same NF-κB pathway, creating a feedback loop where inflammation increases permeability, permeability worsens bacterial translocation, and translocation amplifies inflammation. KPV breaks that cycle without immunosuppression. It modulates, not suppresses.
- LL-37 is the only active cathelicidin antimicrobial peptide in humans, cleaved from the precursor protein hCAP18. It disrupts bacterial membranes through electrostatic interaction and pore formation, killing both gram-positive and gram-negative bacteria without the resistance patterns seen with conventional antibiotics. A 2021 Frontiers in Immunology paper found LL-37 reduced E. coli colony counts by 82% in ileal samples while preserving Lactobacillus populations. Selective antimicrobial action that spares beneficial flora. LL-37 also neutralizes endotoxin, preventing the LPS-driven inflammation that perpetuates barrier dysfunction even after bacterial counts normalize.